Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TC-510 · 1 trial · 17 indications
Phase 1 -The number and percent of patients in the DLT evaluable set who experienced DLTs from the first administration of study drug up to 28 days post study drug treatment will be summarized by dosing group
ORR is defined as incidence of complete responses or partial responses as assessed by RECIST v1.1
DCR defined as a composite of ORR and stable disease (SD) lasting at least 8 weeks.
| Arm | Type | Description |
|---|---|---|
| Lymphodepletion followed by TC-510 | EXPERIMENTAL | Lymphodepletion (fludarabine and cyclophosphamide) followed by TC-510 T cells |
| Name | Type | Description |
|---|---|---|
| TC-510 | BIOLOGICAL | TC-510 |
| Fludarabine | DRUG | Fludarabine |
| Cyclophosphamide | DRUG | Cyclophosphamide |
Inclusion Criteria: * Patient is \> 18 years of age at the time the Informed Consent is signed. * Patient has a pathologically confirmed diagnosis of either MPM, Serous Ovarian Adenocarcinoma, Pancreatic Adenocarcinoma, TNBC, and Colorectal Cancer * Patient's tumor has been reviewed with confirmed ...
TC-510 is an investigational monoclonal antibody being studied for the treatment of mesothelioma and other mesothelin-expressing cancers. It is currently in Phase 1 clinical development for advanced solid tumors, including mesothelioma, ovarian cancer, pancreatic cancer, and non-small cell lung cancer.
TC-510 targets mesothelin, a protein that is overexpressed on the surface of many solid tumors. By binding to mesothelin, TC-510 is designed to direct the immune system against cancer cells that express this protein. It is being evaluated in patients with mesothelin-expressing cancers.
TC-510 is being developed by Adaptimmune Therapeutics PLC (NASDAQ: ADAP). The company is conducting a Phase 1/2 clinical trial of TC-510 in patients with advanced mesothelin-expressing cancers.
TC-510 is in Phase 1 clinical development. It is being studied in an active, not recruiting Phase 1/2 trial (NCT05451849) that is enrolling patients with advanced mesothelin-expressing cancers. The drug is investigational and has not been approved by regulatory authorities.
TC-510 is being evaluated in a single active clinical trial, NCT05451849, titled "A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer." The trial is enrolling 6 participants in the United States and is not currently recruiting. It is an uncontrolled, open-label study.
TC-510 is a distinct investigational monoclonal antibody developed by Adaptimmune Therapeutics. It is not known by any other names. The drug is being studied specifically for its ability to target mesothelin-expressing tumors, including mesothelioma.